DK1567653T3 - Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer - Google Patents

Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer

Info

Publication number
DK1567653T3
DK1567653T3 DK03789029T DK03789029T DK1567653T3 DK 1567653 T3 DK1567653 T3 DK 1567653T3 DK 03789029 T DK03789029 T DK 03789029T DK 03789029 T DK03789029 T DK 03789029T DK 1567653 T3 DK1567653 T3 DK 1567653T3
Authority
DK
Denmark
Prior art keywords
coconut
seq
ati
smallpox virus
recombinant
Prior art date
Application number
DK03789029T
Other languages
English (en)
Inventor
Sonja Leyrer
Paul Howley
Original Assignee
Bavarian Nordic As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic As filed Critical Bavarian Nordic As
Application granted granted Critical
Publication of DK1567653T3 publication Critical patent/DK1567653T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/863Poxviral vectors, e.g. entomopoxvirus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03789029T 2002-11-25 2003-11-12 Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer DK1567653T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200201814 2002-11-25
PCT/EP2003/012610 WO2004048582A2 (en) 2002-11-25 2003-11-12 Recombinant poxvirus comprising at least two cowpox ati promoters

Publications (1)

Publication Number Publication Date
DK1567653T3 true DK1567653T3 (da) 2007-10-15

Family

ID=32337938

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03789029T DK1567653T3 (da) 2002-11-25 2003-11-12 Recombinant koppevirus, som omfatter i det mindste to kokoppe ATI promoterer

Country Status (21)

Country Link
US (1) US7300658B2 (da)
EP (1) EP1567653B1 (da)
JP (1) JP2006515170A (da)
KR (1) KR20050083839A (da)
CN (1) CN1717488A (da)
AT (1) ATE365220T1 (da)
AU (1) AU2003293675B2 (da)
CA (1) CA2501168A1 (da)
CY (1) CY1106883T1 (da)
DE (1) DE60314541T2 (da)
DK (1) DK1567653T3 (da)
EA (1) EA012723B1 (da)
ES (1) ES2288634T3 (da)
IL (1) IL167844A (da)
MX (1) MXPA05005549A (da)
NO (1) NO20053125D0 (da)
NZ (1) NZ540156A (da)
PL (1) PL375740A1 (da)
PT (1) PT1567653E (da)
UA (1) UA85379C2 (da)
WO (1) WO2004048582A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA007811B1 (ru) * 2002-05-16 2007-02-27 Бавариан Нордик А/С Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EP2426142A3 (en) 2006-10-16 2012-06-13 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
JP2012509073A (ja) 2008-11-21 2012-04-19 バヴァリアン・ノルディック・アクティーゼルスカブ 複数の相同ヌクレオチド配列を含むベクター
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
WO2013115884A2 (en) * 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
WO2016115116A1 (en) 2015-01-12 2016-07-21 Geovax, Inc. Compositions and methods for generating an immune response to a hemorrhagic fever virus
KR20160140075A (ko) 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
BR112018010639A2 (pt) * 2015-11-24 2019-01-22 Glaxosmithkline Ip Dev Ltd método de transfecção transitória para produção retroviral.
EP3380604B1 (en) * 2015-11-24 2022-12-28 GlaxoSmithKline Intellectual Property Development Limited Stable cell lines for retroviral production
EP3402802B1 (en) 2016-01-08 2023-04-12 Geovax, Inc. Compositions and methods for generating an immune response to a tumor associated antigen
BR112018015696A2 (pt) 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
KR20230113832A (ko) * 2016-08-09 2023-08-01 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5759841A (en) * 1990-11-20 1998-06-02 Virogenetics Corporation Immunological composition of measles virus utilizing recombinant poxvirus
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
US6682742B1 (en) * 1999-05-28 2004-01-27 Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
US7034141B2 (en) 2000-08-29 2006-04-25 Wyeth Holdings Corporation Packaging of positive-strand RNA virus replicon particles

Also Published As

Publication number Publication date
UA85379C2 (ru) 2009-01-26
JP2006515170A (ja) 2006-05-25
CN1717488A (zh) 2006-01-04
PT1567653E (pt) 2007-10-01
CY1106883T1 (el) 2012-09-26
EP1567653B1 (en) 2007-06-20
EA200500879A1 (ru) 2005-10-27
NO20053125L (no) 2005-06-24
AU2003293675B2 (en) 2009-04-23
EP1567653A2 (en) 2005-08-31
EA012723B1 (ru) 2009-12-30
DE60314541D1 (de) 2007-08-02
PL375740A1 (en) 2005-12-12
KR20050083839A (ko) 2005-08-26
US7300658B2 (en) 2007-11-27
WO2004048582A3 (en) 2004-08-12
AU2003293675A1 (en) 2004-06-18
NO20053125D0 (no) 2005-06-24
NZ540156A (en) 2006-11-30
ATE365220T1 (de) 2007-07-15
IL167844A (en) 2011-03-31
ES2288634T3 (es) 2008-01-16
WO2004048582A2 (en) 2004-06-10
CA2501168A1 (en) 2004-06-10
DE60314541T2 (de) 2008-02-28
MXPA05005549A (es) 2005-08-16
US20060153874A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
NO20053125L (no) Rekombinant koppevirus omfattende i det minste to kukoppe-ati-promotere.
HK1076835A1 (en) Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter
ES2256323T3 (es) Variante del virus vaccinia ankara modificado.
UA82998C2 (ru) Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті
US6869793B2 (en) Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
JP2001081042A5 (da)
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
CN101142319B (zh) 基于使用修饰安卡拉痘苗病毒的疫苗
BR0011159A (pt) Método para produzir vacinas de vìrus rna de fita negativa atenuado a partir de sequências de nucleotìdeos clonados
WO2003023040A3 (en) Vaccinia virus mva-e3l-knockout-mutants and use thereof
EP1855720B2 (en) Use of a modified proxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
BR0012512A (pt) Genes de calicivìrus felino e vacinas notadamente vacinas recombinadas
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
WO2003040305A3 (en) Porcine adenovirus e1 and e4 regions
CA2372709A1 (en) Vector for integration of heterologous sequences into poxviral genomes
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
JP2009232836A5 (da)
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
CA2351010A1 (en) A broad spectrum infectious bursal disease virus vaccine
BR0316553A (pt) Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina
MX2023006688A (es) Eliminacion genomica en la vacuna contra la peste porcina africana que permite un crecimiento eficaz en estirpes celulares estables.
DK200201813A (da) Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper
Cheng et al. 106 Gln Glu Glu 122 Met Met Val
JP2004525885A5 (da)